Welcome to the Ulcerative Colitis Resource Center, brought to you by Healio.com/Gastroenterology. Here you'll find the latest information on the diagnosis, management and treatment of ulcerative colitis, as well as up-to-date material on future research. Be sure to check out Healio.com/Gastroenterology for more news and perspective important to your practice.
In the Journals
April 24, 2019
The addition of biologics and using an early step-up approach to therapy has helped improve outcomes among children with ulcerative colitis over the…
In the Journals
April 17, 2019
Since implementing its Inpatient Ulcerative Colitis Protocol in 2016, the University of California San Francisco has improved the uniform application…
In the JournalsPerspective
April 1, 2019
In a direct comparison with Humira, Entyvio won out as the top choice for second line therapy for patients with ulcerative colitis who failed therapy…
In the Journals
March 29, 2019
Eosinophilic esophagitis and inflammatory bowel disease have a connection in which patients with one are at higher risk for the other, according to…
Meeting News
March 28, 2019
Two different dosing regimens of Stelara helped patients with moderate-to-severe ulcerative colitis achieve clinical remission and maintain a…
In the Journals
March 26, 2019
Roughly one-fifth of all prescriptions for inflammatory bowel disease are considered “off-label” with one-third of all patients receiving…
March 23, 2019
Theravance Biopharma has announced the first patient dosing in a phase 2b/3 study of TD-1473 in patients with moderately to severely active…
In the Journals
March 21, 2019
Lower attrition rates observed in a year-long study revealed that patients with inflammatory bowel disease are more receptive to an improved…
Meeting News
March 14, 2019
Patients with early Crohn’s disease who can achieve endoscopic or deep remission after one year of treatment are less likely to experience…
Meeting News
March 13, 2019
Final results from the GEMINI trial revealed that Entyvio had a suitable safety profile for long-term treatment of inflammatory bowel disease…